British pharmaceutical company AstraZeneca reports that data resulting from a late-stage clinical trial investigating whether its diabetes drug called Farxiga can treat patients hospitalized with…
Another National Institute of Allergy and Infectious Diseases (NIAID)-backed large scale COVID-19 experiment failed to meet endpoints as the CoVIg-19 Plasma Alliance recently shared that…
Orphazyme announced the phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (IBM), a progressively debilitating muscle-wasting disease, did not meet its…
Wave Life Sciences announced data from the Phase 1b/2a PRECISION-HD2 and PRECISION-HD1 trials evaluating WVE-120102 and WVE-120101, respectively, in Huntington’s disease (HD). Neither trial met…
A group of South African-based researchers known as the NGS-SA Groups Wits (VIDA COVID Group) recently investigated the safety and efficacy of vaccines against COVID-19…
Those monitoring progress in cystic fibrosis therapies were disappointed Wednesday when a messenger RNA-based biotech company called Translate Bio shared trial data that although safe,…
Although some studies have evidenced to the contrary, the anti-inflammatory drug called Actemra combined with Veklury (remdesivir) did not lead to reduced hospitalization as has…
The National Institutes of Health (NIH) sponsored Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partners involved with determining where federal research dollars are…
Recently, the results of a new ivermectin study out of Columbia were reported in the medical journal JAMA. Led by Eduardo Lopez Medina, MD, a physician…
A recent study sponsored by Massachusetts General Hospital in collaboration with the National Multiple Sclerosis Society and Pillsy Inc. was based on the assumption that…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
